E-mail Alerts

You may automatically receive Aimmune Therapeutics' financial information by email. To choose your options, please enter your email address below and click submit. On the next page, you will be able to choose from the following options:

Required fields denoted by an asterisk ().

Alert type
Aimmune Therapeutics News Alert

ShareThis Copy and Paste

Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT

Webcast Presentation

Help

Click here for webcast

— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...